Fibrocell Science (FCSC) Upgraded at Zacks Investment Research
Fibrocell Science (NASDAQ:FCSC) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday. The firm currently has a $2.25 target price on the stock. Zacks Investment Research‘s target price would suggest a potential upside of 12.50% from the company’s previous close.
According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
A number of other research analysts also recently weighed in on FCSC. ValuEngine raised shares of Fibrocell Science from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of Fibrocell Science in a research report on Tuesday, November 13th. Finally, Canaccord Genuity reduced their target price on shares of Fibrocell Science from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, October 15th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $11.42.
Fibrocell Science (NASDAQ:FCSC) last released its earnings results on Tuesday, November 13th. The company reported ($0.28) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.83) by $0.55. As a group, sell-side analysts expect that Fibrocell Science will post -3.84 EPS for the current fiscal year.
An institutional investor recently bought a new position in Fibrocell Science stock. Virtu Financial LLC purchased a new stake in shares of Fibrocell Science Inc (NASDAQ:FCSC) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 48,914 shares of the company’s stock, valued at approximately $120,000. Virtu Financial LLC owned approximately 0.53% of Fibrocell Science at the end of the most recent quarter. Institutional investors own 26.86% of the company’s stock.
Fibrocell Science Company Profile
Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
Featured Article: Momentum Indicator: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.